Match Group(MTCH) - 2025 Q4 - Annual Report
2026-02-26 21:51
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year EndDedecember 31, 2025 Commission File No. 001-34148 Match Group, Inc. (Exact name of registrant as specified in its charter) Delaware 59-2712887 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8750 North Central Expressway , Suite 1400, Dallas, Texas75231 (Address of Re ...
Arlo(ARLO) - 2025 Q4 - Annual Results
2026-02-26 21:50
NEWS RELEASE Arlo Reports Fourth Quarter and Full Year 2025 Results Annual recurring revenue (ARR) ended at $330 million, growing 28% year over year (1) Q4 2025 Financial Summary Full Year 2025 Financial Summary Page 1 • Ended with ARR of $330.5 million, growing 28.4% year over year. (1) • Record subscriptions and services revenue of $89.4 million, an increase of 39.4% year over year, accounting for 63.3% of total revenues. • GAAP subscriptions and services gross margin of 82.8% and non-GAAP subscriptions a ...
Kinetik (KNTK) - 2025 Q4 - Annual Report
2026-02-26 21:50
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38048 KINETIK HOLDINGS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporati ...
Cactus(WHD) - 2025 Q4 - Annual Report
2026-02-26 21:50
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or For the transition period from to Commission File Number: 001-38390 Cactus, Inc. (Exact name of registrant as specified in its charter) Delaware 35-2586106 (State or other juri ...
Victory Capital(VCTR) - 2025 Q4 - Annual Report
2026-02-26 21:49
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM to Commission file number: 001-38388 Victory Capital Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0402956 (S ...
Atlantic Union Bankshares (AUB) - 2025 Q4 - Annual Report
2026-02-26 21:45
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39325 ATLANTIC UNION BANKSHARES CORPORATION (Exact name of registrant as specified in its charter) Virginia 54-1598552 (State or other jurisdiction of (I.R.S. Emp ...
MP Materials(MP) - 2025 Q4 - Annual Report
2026-02-26 21:45
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-39277 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 MP MATERIALS CORP. (Exact name of registrant as specified in its charter) Delaware 84-4 ...
Amphastar Pharmaceuticals(AMPH) - 2025 Q4 - Annual Report
2026-02-26 21:41
Financial Position - The company has $111.4 million in cash equivalents, including money market accounts, as of December 31, 2025[582]. - The company had $96.1 million in investment grade corporate and municipal bonds as of December 31, 2025[582]. - The company experienced a decline in cash equivalents from $102.1 million in 2024 to $111.4 million in 2025, indicating a growth in liquidity[582][583]. - The company maintains significant cash balances exceeding federally insured limits, which poses a normal business risk[584]. - As of December 31, 2025, the company had $610.4 million in long-term debt and finance leases, all with fixed interest rates or locked-in fixed rates through swap contracts[586]. Tax and Regulatory Risks - The company is subject to changes in tax laws, such as the 1% excise tax on stock repurchases and a 15% alternative minimum tax on adjusted financial statement income[468]. - The company is evaluating the impact of the OBBB Act on its financial position and results of operations[468]. - The company is subject to significant judgment in determining its worldwide provision for income taxes, which may lead to material differences in tax audits[469]. Market Risks - The company is exposed to market risks including investment risk, interest rate risk, and foreign currency exchange risk[580]. - The company is primarily exposed to interest rate risk through interest rate sensitive investments and credit facilities, but believes it is not subject to material risk with respect to short-term investments[585]. - The company's operations in France are exposed to market risk related to changes in foreign currency exchange rates due to sales contracts frequently denominated in euros[587]. Foreign Currency Exposure - A theoretical 10% unfavorable change in the exchange rate of the U.S. dollar against foreign currencies would result in approximately $0.1 million reduction of foreign currency gains and approximately $3.6 million reduction in other comprehensive income as of December 31, 2025[591]. - As of December 31, 2024, a theoretical 10% unfavorable change in the exchange rate would lead to approximately $1.2 million reduction of foreign currency gains and approximately $3.1 million reduction in other comprehensive income[592]. - The company's foreign subsidiaries had cash balances in foreign currencies amounting to $7.7 million and $6.6 million as of December 31, 2025 and 2024, respectively[592]. - The company may enter into derivative contracts to manage interest-rate exposures and achieve a balance between fixed- and floating-rate debt[585]. - The unrealized gains or losses from intercompany foreign currency transactions of a long-term investment nature are reported in other accumulated comprehensive income (loss)[589]. - The company's Chinese subsidiary maintains its books in Chinese yuan, which are remeasured into USD using current or historical exchange rates[588]. - The company is exposed to potential earnings effects from intercompany foreign currency assets and liabilities arising from normal trade receivables and payables[590]. Operational Risks - The company’s operating results may fluctuate significantly due to various factors, including the commercial success of key products and regulatory actions[475]. - The company recorded no declines in fair value of investments that are considered other than temporary as of December 31, 2025[581].
Puma Biotechnology(PBYI) - 2025 Q4 - Annual Report
2026-02-26 21:41
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State o ...
PJT Partners (PJT) - 2025 Q4 - Annual Report
2026-02-26 21:40
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36869 PJT Partners Inc. (Exact name of Registrant as specified in its Charter) Delaware 36-4797143 (State or other jurisdiction of in ...